Monivent (MONI) Q4 2025 earnings summary

Executive summary

• Focused on regulatory progress and commercial strategy, nearing product launch with Dräger and planning geographic expansion.

• Achieved first US patent, strengthening product protection; ongoing MDR and FDA approval processes.

• Improved EBIT and cost control despite lower sales; direct sales efforts ongoing ahead of Dräger distribution.

Financial highlights

• Net sales for 2025 were 1,424 KSEK, down from 2,142 KSEK year-over-year.

• EBIT improved to -8,546 KSEK from -11,203 KSEK year-over-year.

• Cash at year-end was 399 KSEK, down from 970 KSEK prior year.

• Equity ratio increased to 21% from 11% year-over-year.

• No dividend proposed for the year.

Outlook and guidance

• MDR approval expected by end of Q2 2026; US FDA submission planned for H1 2026.

• Launch of Neo100 in Europe to follow MDR approval; US launch after FDA clearance.

• Ongoing efforts to secure long-term financing.